| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	-SEC Filing
 
																	
 
																	
 
																	 
																	 
																	HC Wainwright & Co. analyst Ed Arce upgrades Synlogic (NASDAQ:SYBX) from Sell to Neutral.
 
																	Synlogic (NASDAQ:SYBX) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.97) by...
 
																	Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious disease...